Have any questions? 706-721-6582 or cts@augusta.edu
- MS201943-0029: A Phase Ib, Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Clinical Trial
MS201943-0029: A Phase Ib, Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
M6620 is an investigational drug, avelumab is an investigational drug for ovarian cancer and carboplatin is an approved drug ovarian cancer. The combination of the three drugs being tested for subjects with recurrent ovarian, primary peritoneal, or fallopian tube cancer is investigational. This combination treatment will be tested in subjects who responded well to previous treatment with poly (ADP ribose) polymerase inhibitor (PARPi) and have recurrent of their cancer.
- Female Reproductive System
- Cancer
- Fallopian Tube Cancer
- Oncology
- Ovarian Cancer
- Primary Peritoneal Cancer
Eligibility Criteria
- participants must be at least 18 years of age or older with a confirmed BRCA 1/2 mutation status or agree to its testing on samples collected in the study. They must also have measurable disease according to RECICT v1.1. Participants may not have had prior organ transplant, including allogenic transplatation.
RESEARCH. INNOVATION. DISCOVERY.